Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Blood Cancer Discov ; 5(1): 34-55, 2024 01 08.
Artigo em Inglês | MEDLINE | ID: mdl-37767768

RESUMO

Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. SIGNIFICANCE: These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM. See related article by Neri, Barwick, et al., p. 56. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4.


Assuntos
Mieloma Múltiplo , Humanos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/genética , Lenalidomida/farmacologia , Lenalidomida/uso terapêutico , Fator de Transcrição AP-1/uso terapêutico , Combinação de Medicamentos , Agentes de Imunomodulação
2.
Sci Rep ; 9(1): 4544, 2019 03 14.
Artigo em Inglês | MEDLINE | ID: mdl-30872698

RESUMO

Many tumors maintain chromosome-ends through a telomerase-independent, DNA-templated mechanism called alternative lengthening of telomeres (ALT). While ALT occurs in only a subset of tumors, it is strongly associated with mutations in the genes ATRX and DAXX, which encode components of an H3.3 histone chaperone complex. The role of ATRX and DAXX mutations in potentiating the mechanism of ALT remains incompletely understood. Here we characterize an osteosarcoma cell line, G292, with wild-type ATRX but a unique chromosome translocation resulting in loss of DAXX function. While ATRX and DAXX form a complex in G292, this complex fails to localize to nuclear PML bodies. We demonstrate that introduction of wild type DAXX suppresses the ALT phenotype and restores the localization of ATRX/DAXX to PML bodies. Using an inducible system, we show that ALT-associated PML bodies are disrupted rapidly following DAXX induction and that ALT is again restored following withdrawal of DAXX.


Assuntos
Neoplasias Ósseas/genética , Proteínas Correpressoras/genética , Chaperonas Moleculares/genética , Mutação , Osteossarcoma/genética , Homeostase do Telômero , Neoplasias Ósseas/patologia , Humanos , Osteossarcoma/patologia , Fenótipo , Telomerase/genética , Telomerase/metabolismo , Células Tumorais Cultivadas
3.
PLoS One ; 12(8): e0182610, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28787462

RESUMO

A new ovarian near-diploid cell line, OVDM1, was derived from a highly aneuploid serous ovarian metastatic adenocarcinoma. A metastatic tumor was obtained from a 47-year-old Ashkenazi Jewish patient three years after the first surgery removed the primary tumor, both ovaries, and the remaining reproductive organs. OVDM1 was characterized by cell morphology, genotyping, tumorigenic assay, mycoplasma testing, spectral karyotyping (SKY), and molecular profiling of the whole genome by aCGH and gene expression microarray. Targeted sequencing of a panel of cancer-related genes was also performed. Hierarchical clustering of gene expression data clearly confirmed the ovarian origin of the cell line. OVDM1 has a near-diploid karyotype with a low-level aneuploidy, but samples of the original metastatic tumor were grossly aneuploid. A number of single nucleotide variations (SNVs)/mutations were detected in OVDM1 and the metastatic tumor samples. Some of them were cancer-related according to COSMIC and HGMD databases (no founder mutations in BRCA1 and BRCA2 have been found). A large number of focal copy number alterations (FCNAs) were detected, including homozygous deletions (HDs) targeting WWOX and GATA4. Progression of OVDM1 from early to late passages was accompanied by preservation of the near-diploid status, acquisition of only few additional large chromosomal rearrangements and more than 100 new small FCNAs. Most of newly acquired FCNAs seem to be related to localized but massive DNA fragmentation (chromothripsis-like rearrangements). Newly developed near-diploid OVDM1 cell line offers an opportunity to evaluate tumorigenesis pathways/events in a minor clone of metastatic ovarian adenocarcinoma as well as mechanisms of chromothripsis.


Assuntos
Aneuploidia , Linhagem Celular Tumoral , Diploide , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , Adulto , Animais , Transformação Celular Neoplásica , Progressão da Doença , Feminino , Perfilação da Expressão Gênica , Genômica , Humanos , Camundongos , Metástase Neoplásica , Estadiamento de Neoplasias
4.
Genes Chromosomes Cancer ; 53(6): 467-74, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24585545

RESUMO

Primary IGH translocations involving seven recurrent partner loci and oncogenes are present in about 40% of multiple myeloma tumors. Secondary IGH rearrangements, which occur in a smaller fraction of tumors, usually are complex structures, including insertions or translocations that can involve three chromosomes, and often with involvement of MYC. The main approach to detect IGH rearrangements is interphase-but sometimes metaphase-FISH strategies that use a telomeric variable region probe and a centromeric constant region/ Eα enhancer or 3' flanking probe to detect a separation of these two probes, or a fusion of these probes with probes located at nonrandom partner sites in the genome. We analyzed 18 myeloma cell lines for detection discrepancies among Vysis, Cytocell, and in-house IGH probe sets that hybridize with differing sequences in the IGH locus. There were no detection discrepancies for the three telomeric IGH probes, or for unrearranged IGH loci or primary IGH translocations using the centromeric IGH probes. However, the majority of complex IGH rearrangements had detection discrepancies among the three centromeric IGH probes.


Assuntos
Sondas de DNA/química , Rearranjo Gênico , Cadeias Pesadas de Imunoglobulinas/genética , Mieloma Múltiplo/genética , Linhagem Celular Tumoral , Cromossomos Humanos/genética , Humanos , Hibridização in Situ Fluorescente , Interfase , Mieloma Múltiplo/patologia , Mutagênese Insercional , Translocação Genética
5.
Leukemia ; 28(8): 1725-1735, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24518206

RESUMO

MYC locus rearrangements-often complex combinations of translocations, insertions, deletions and inversions-in multiple myeloma (MM) were thought to be a late progression event, which often did not involve immunoglobulin genes. Yet, germinal center activation of MYC expression has been reported to cause progression to MM in an MGUS (monoclonal gammopathy of undetermined significance)-prone mouse strain. Although previously detected in 16% of MM, we find MYC rearrangements in nearly 50% of MM, including smoldering MM, and they are heterogeneous in some cases. Rearrangements reposition MYC near a limited number of genes associated with conventional enhancers, but mostly with super-enhancers (e.g., IGH, IGL, IGK, NSMCE2, TXNDC5, FAM46C, FOXO3, IGJ, PRDM1). MYC rearrangements are associated with a significant increase of MYC expression that is monoallelic, but MM tumors lacking a rearrangement have biallelic MYC expression at significantly higher levels than in MGUS. We also have shown that germinal center activation of MYC does not cause MM in a mouse strain that rarely develops spontaneous MGUS. It appears that increased MYC expression at the MGUS/MM transition usually is biallelic, but sometimes can be monoallelic if there is an MYC rearrangement. Our data suggest that MYC rearrangements, regardless of when they occur during MM pathogenesis, provide one event that contributes to tumor autonomy.


Assuntos
Elementos Facilitadores Genéticos , Rearranjo Gênico , Genes myc , Mieloma Múltiplo/genética , Animais , Hibridização Genômica Comparativa , Regulação Neoplásica da Expressão Gênica , Genes de Imunoglobulinas , Humanos , Hibridização in Situ Fluorescente , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL
6.
Front Oncol ; 3: 302, 2013 Dec 11.
Artigo em Inglês | MEDLINE | ID: mdl-24377086

RESUMO

Whole-chromosomal instability (W-CIN) - unequal chromosome distribution during cell division - is a characteristic feature of a majority of cancer cells distinguishing them from their normal counterparts. The precise molecular mechanisms that may cause mis-segregation of chromosomes in tumor cells just recently became more evident. The consequences of W-CIN are numerous and play a critical role in carcinogenesis. W-CIN mediates evolution of cancer cell population under selective pressure and can facilitate the accumulation of genetic changes that promote malignancy. It has both tumor-promoting and tumor-suppressive effects, and their balance could be beneficial or detrimental for carcinogenesis. The characterization of W-CIN as a complex multi-layered adaptive phenotype highlights the intra- and extracellular adaptations to the consequences of genome reshuffling. It also provides a framework for targeting aggressive chromosomally unstable cancers.

7.
Cancer Genet ; 206(5): 191-205, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23830731

RESUMO

High-resolution oligonucleotide array comparative genomic hybridization (aCGH) and spectral karyotyping (SKY) were applied to a panel of malignant mesothelioma (MMt) cell lines. SKY has not been applied to MMt before, and complete karyotypes are reported based on the integration of SKY and aCGH results. A whole genome search for homozygous deletions (HDs) produced the largest set of recurrent and non-recurrent HDs for MMt (52 recurrent HDs in 10 genomic regions; 36 non-recurrent HDs). For the first time, LINGO2, RBFOX1/A2BP1, RPL29, DUSP7, and CCSER1/FAM190A were found to be homozygously deleted in MMt, and some of these genes could be new tumor suppressor genes for MMt. Integration of SKY and aCGH data allowed reconstruction of chromosomal rearrangements that led to the formation of HDs. Our data imply that only with acquisition of structural and/or numerical karyotypic instability can MMt cells attain a complete loss of tumor suppressor genes located in 9p21.3, which is the most frequently homozygously deleted region. Tetraploidization is a late event in the karyotypic progression of MMt cells, after HDs in the 9p21.3 region have already been acquired.


Assuntos
Deleção de Genes , Neoplasias Pulmonares/genética , Mesotelioma/genética , Linhagem Celular Tumoral , Aberrações Cromossômicas , Cromossomos Humanos Par 9 , Hibridização Genômica Comparativa , Humanos , Mesotelioma Maligno , Cariotipagem Espectral
8.
Curr Drug Targets ; 11(10): 1341-50, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20840077

RESUMO

Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable "states" that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.


Assuntos
Antineoplásicos/farmacologia , Instabilidade Cromossômica , Neoplasias/tratamento farmacológico , Animais , Aberrações Cromossômicas , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Resistencia a Medicamentos Antineoplásicos , Humanos , Neoplasias/genética , Neoplasias/patologia , Fenótipo
9.
Mutat Res ; 683(1-2): 115-22, 2010 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-19909760

RESUMO

Aberrant repair of DNA double-strand breaks (DSBs) is thought to be important in the generation of gross chromosomal rearrangements (GCRs). To examine how DNA DSBs might lead to GCRs, we investigated the repair of a single DNA DSB in a structurally unstable cell line. An I-SceI recognition site was introduced into OVCAR-8 cells between a constitutive promoter (EF1alpha) and the Herpes simplex virus thymidine kinase (TK) gene, which confers sensitivity to gancyclovir (GCV). Expression of I-SceI in these cells caused a single DSB. Clones with aberrant repair could acquire resistance to GCV by separation of the EF1alpha promoter from the TK gene, or deletion of either the EF1alpha promoter or the TK gene. All mutations that we identified were interstitial deletions. Treatment of cells with etoposide or bleomycin, agents known to produce DNA DSBs following expression of I-SceI also did not generate GCRs. Because we identified solely interstitial deletions using the aforementioned negative selection system, we developed a positive selection system to produce GCR. A construct containing an I-SceI restriction site immediately followed by a hygromycin phosphotransferase cDNA, with no promoter, was stably integrated into OVCAR-8 cells. DNA DSBs were produced by an I-SceI expression vector. None of the hygromycin resistant clones recovered had linked the hygromycin phosphotransferase cDNA to an endogenous promoter, but had instead captured a portion of the I-SceI expression vector. These results indicate that even in a structurally unstable malignant cell line, the majority of DNA DSBs are repaired by religation of the two broken chromosome ends, without the introduction of a GCR.


Assuntos
Aberrações Cromossômicas , Quebras de DNA de Cadeia Dupla , Reparo do DNA/genética , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , Antineoplásicos Fitogênicos/farmacologia , Antivirais/farmacologia , Southern Blotting , Coloração Cromossômica , Cinamatos/farmacologia , Resistencia a Medicamentos Antineoplásicos/genética , Etoposídeo/farmacologia , Feminino , Ganciclovir/farmacologia , Humanos , Higromicina B/análogos & derivados , Higromicina B/farmacologia , Hibridização in Situ Fluorescente , Fator 1 de Elongação de Peptídeos/genética , Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo , Plasmídeos , Regiões Promotoras Genéticas/genética , Timidina Quinase/genética , Células Tumorais Cultivadas
10.
Neoplasia ; 10(11): 1222-30, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18953431

RESUMO

Chromosomal instability-a hallmark of epithelial cancers-is an ongoing process that results in aneuploidy and karyotypic heterogeneity of a cancer cell population. Previously, we stratified cancer cell lines in the NCI-60 drug discovery panel based on their karyotypic complexity and heterogeneity. Using this stratification in conjunction with drug response data for the cell lines allowed us to identify classes of chemical compounds whose growth-inhibitory activity correlates with karyotypic complexity and chromosomal instability. In this article, we asked the question: What are the biological processes, pathways, or genes associated with chromosomal instability of cancer cells? We found that increased instability of the chromosomal content in a cancer cell population, particularly, persistent gains and losses of chromosomes, is associated with elevated expression of genes involved with aggressive cellular behavior, including invasion- and metastasis-associated changes in cell communication, adhesion, motility, and migration. These same karyotypic features are negatively correlated with the expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance.


Assuntos
Instabilidade Cromossômica , Regulação Neoplásica da Expressão Gênica , Invasividade Neoplásica/genética , Metástase Neoplásica/genética , Neoplasias/genética , Análise de Variância , Adesão Celular , Comunicação Celular , Ciclo Celular/genética , Linhagem Celular Tumoral , Montagem e Desmontagem da Cromatina/genética , Aberrações Cromossômicas , Reparo do DNA/genética , Bases de Dados de Ácidos Nucleicos , Células Epiteliais , Humanos , Cariotipagem , Células-Tronco Mesenquimais , Neoplasias/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Transdução de Sinais
11.
J Exp Med ; 204(3): 633-43, 2007 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-17353367

RESUMO

To elucidate the mechanisms underlying chromosomal translocations in diffuse large B cell lymphoma (DLBCL), we investigated the nature and extent of immunoglobulin class switch recombination (CSR) in these tumors. We used Southern blotting to detect legitimate and illegitimate CSR events in tumor samples of the activated B cell-like (ABC), germinal center B cell-like (GCB), and primary mediastinal B cell lymphoma (PMBL) subgroups of DLBCL. The frequency of legitimate CSR was lower in ABC DLBCL than in GCB DLBCL and PMBL. In contrast, ABC DLBCL had a higher frequency of internal deletions within the switch mu (Smu) region compared with GCB DLBCL and PMBL. ABC DLBCLs also had frequent deletions within Sgamma and other illegitimate switch recombinations. Sequence analysis revealed ongoing Smu deletions within ABC DLBCL tumor clones, which were accompanied by ongoing duplications and activation-induced cytidine deaminase-dependent somatic mutations. Unexpectedly, short fragments derived from multiple chromosomes were interspersed within Smu in one case. These findings suggest that ABC DLBCLs have abnormalities in the regulation of CSR that could predispose to chromosomal translocations. Accordingly, aberrant switch recombination was responsible for translocations in ABC DLBCLs involving BCL6, MYC, and a novel translocation partner, SPIB.


Assuntos
Switching de Imunoglobulina/imunologia , Ativação Linfocitária/genética , Linfoma de Células B/imunologia , Linfoma Difuso de Grandes Células B/imunologia , Recombinação Genética , Translocação Genética , Linhagem Celular Tumoral , Humanos , Switching de Imunoglobulina/genética , Linfoma de Células B/genética , Linfoma de Zona Marginal Tipo Células B/genética , Linfoma de Zona Marginal Tipo Células B/imunologia , Linfoma Difuso de Grandes Células B/genética , Células Tumorais Cultivadas
12.
Mol Cancer Ther ; 4(10): 1559-68, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16227406

RESUMO

The karyotypic features of cancer cells have not been a particular focus of anticancer drug targeting either as guidance for treatment or as specific drug targets themselves. Cancer cell lines typically have considerable, characteristic, and variable chromosomal aberrations. Here, we consider small-molecule screening data across the National Cancer Institute's 60 tumor cell line drug screening panel (NCI-60) analyzed for specific association with karyotypic variables (numerical and structural complexity and heterogeneity) determined for these same cell lines. This analysis is carried out with the aid of a self-organizing map allowing for a simultaneous assessment of all screened compounds, revealing an association between karyotypic variables and a unique part of the cytotoxic response space. Thirteen groups of compounds based on related specific chemical structural motifs are identified as possible leads for anticancer drug discovery. These compounds form distinct groups of molecules associated with relatively unexplored regions of the NCI-60 self-organizing map where anticancer agents currently standard in the clinic are not present. We suggest that compounds identified in this study may represent new classes of potential anticancer agents.


Assuntos
Antineoplásicos/farmacologia , Neoplasias/tratamento farmacológico , Neoplasias/genética , Antineoplásicos/classificação , Linhagem Celular Tumoral , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Cariotipagem Espectral
13.
Cell Cycle ; 4(5): 679-82, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15846096

RESUMO

Multiple karyotypic abnormalities and chromosomal instability are particular hallmarks of many cancers that are relatively resistant to long term control by current chemotherapeutic agents. We have asked whether these same hallmarks, karyotypic complexity and instability, can be used as determinants for the screening of potential anticancer compounds. Using a panel of well characterized cancer cell lines we have been able to identify specific groups of chemical compounds that are more cytotoxic toward the relatively more karyotypically complex and unstable panel members. Thus, we delineate an approach for the identification of "lead compounds" for anticancer drug discovery complementary to approaches that are focused at the outset on a given gene or pathway.


Assuntos
Antineoplásicos/farmacologia , Instabilidade Cromossômica , Aberrações Cromossômicas , DNA de Neoplasias/genética , Neoplasias/tratamento farmacológico , Neoplasias/genética , Antineoplásicos/uso terapêutico , Linhagem Celular Tumoral , Instabilidade Cromossômica/genética , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Resistencia a Medicamentos Antineoplásicos/genética , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Regulação Neoplásica da Expressão Gênica , Genes Neoplásicos , Humanos
14.
Proc Natl Acad Sci U S A ; 102(8): 2964-9, 2005 Feb 22.
Artigo em Inglês | MEDLINE | ID: mdl-15703300

RESUMO

Cancer is a genetic disease caused by genomic instability. In many cancers, this instability is manifested by chromosomal reconfigurations and karyotypic complexity. These features are particular hallmarks of the epithelial cancers that are some of the malignancies most resistant to long term control by current chemotherapeutic agents. We have asked whether we could use karyotypic complexity and instability as determinants for the screening of potential anticancer compounds. Using a panel of well characterized cancer cell lines, we have been able to identify specific groups of chemical compounds that are more cytotoxic toward the relatively more karyotypically complex and unstable panel members. Thus, we delineate an approach for the identification of "lead compounds" for anticancer drug discovery complementary to those that are focused at the outset on a given gene or pathway.


Assuntos
Aberrações Cromossômicas , Desenho de Fármacos , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Cariotipagem
15.
Cancer Res ; 63(24): 8634-47, 2003 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-14695175

RESUMO

We used spectral karyotyping to provide a detailed analysis of karyotypic aberrations in the diverse group of cancer cell lines established by the National Cancer Institute for the purpose of anticancer drug discovery. Along with the karyotypic description of these cell lines we defined and studied karyotypic complexity and heterogeneity (metaphase-to-metaphase variations) based on three separate components of genomic anatomy: (a) ploidy; (b) numerical changes; and (c) structural rearrangements. A wide variation in these parameters was evident in these cell lines, and different association patterns between them were revealed. Analysis of the breakpoints and other specific features of chromosomal changes across the entire set of cell lines or within particular lineages pointed to a striking lability of centromeric regions that distinguishes the epithelial tumor cell lines. We have also found that balanced translocations are as frequent in absolute number within the cell lines derived from solid as from hematopoietic tumors. Important similarities were noticed between karyotypic changes in cancer cell lines and that seen in primary tumors. This dataset offers insights into the causes and consequences of the destabilizing events and chromosomal instability that may occur during tumor development and progression. It also provides a foundation for investigating associations between structural genome anatomy and cancer molecular markers and targets, gene expression, gene dosage, and resistance or sensitivity to tens of thousands of molecular compounds.


Assuntos
Linhagem Celular Tumoral , Aberrações Cromossômicas , Neoplasias/genética , Reparo do DNA/genética , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Neoplasias/patologia , Ploidias , Proteína do Retinoblastoma/genética , Cariotipagem Espectral , Translocação Genética , Proteína Supressora de Tumor p53/genética
16.
Neoplasia ; 4(1): 19-31, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11922387

RESUMO

Most human tumors and tumor cell lines exhibit numerical and structural chromosomal abnormalities. The goal of this study was to determine the ongoing rates of structural and numerical instability in selected cancer cell lines and to investigate the consequences of these rates to karyotypic progression. We studied two colorectal (HCT-116 and HT-29) and two ovarian (SKOV-3 and OVCAR-8) cancer cell lines and their single cell subclones. We found that the signature karyotypes of all four cell lines were distinct and each aberrant. Whereas high rates of ongoing structural and/ or numerical chromosomal instability could be demonstrated in all cell lines, there was a relative stability of the consensus karyotype over many generations. No new clonal structural chromosomal reconfigurations emerged and the few numerical changes of karyotypes were restricted to abnormal chromosomes. This implies a kind of genomic optimization under the conditions of cell culture and suggests a link between genomic stabilization and cell propagation. We have been able to support this possibility by computer modeling. We did not observe a profound difference in the rates of numerical or structural instability in the cell lines with a replication error phenotype (RER+) versus the other cell lines.


Assuntos
Aberrações Cromossômicas , Neoplasias Colorretais/genética , Neoplasias Epiteliais e Glandulares/genética , Neoplasias Ovarianas/genética , Biologia Computacional , Simulação por Computador , Feminino , Humanos , Hibridização in Situ Fluorescente , Cariotipagem , Metáfase , Hibridização de Ácido Nucleico , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA